WeedMD Reports Second Quarter 2020 Financial Results and Closes $30 Million Credit Facility with LiUNA Pension Fund TSX Venture Exchange:WMD

September 30, 2020 Off By administrator

TORONTO, Sept. 30, 2020 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, announced today its financial results for the three months ended June 30, 2020.

WeedMD reported net revenue of $5.9 million for the second quarter of 2020 driven by direct-to-consumer sales in the medical market and provincial retail channels. The Company also strengthened its liquidity subsequent to quarter end by closing on a $30 million credit facility with strategic investor LiUNA Pension Fund of Eastern and Central Canada (“LPF”).

“During the second quarter, we advanced our integration with Starseed to drive direct-to-consumer revenue and made significant operational progress in ramping up production. Our unique medical service platform and growing brand recognition for our Color Cannabis adult-use products contributed to our revenue for the quarter,” said Angelo Tsebelis, CEO of WeedMD. “We also entered into multiple new strategic partnerships and new consumer categories during the quarter, with expanded products manufactured from our own input biomass at our extraction hub. Complementing this, we anticipate an impressive harvest from our outdoor platform this fall. In recent weeks, we have seen an increase in customer activity and sales as consumers continue to adjust to COVID-19. The continued support and $30 million in non-dilutive financing we received from our partner and strategic investor LPF will provide us with increased liquidity to support our future sales growth.”

Summary of Results

For the Quarter-Ended June 30, 2020   June 30, 2019  
  ($000’s)   ($000’s)  
Net revenue 5,859   7,980  
Gross (loss) profit before changes in fair value (898 ) 3,663  
Gross margin % before changes in fair value (15 %) 46 %
Income (loss) and comprehensive (loss) (8,895 ) 12,625  
Adjusted EBITDA* (loss) (4,951 ) (729 )
As at June 30, 2020   Dec. 31, 2019  
  ($000’s)   ($000’s)  
Cash and cash equivalents 5,667   8,184  
Inventory 35,002   31,287  
Biological assets 3,611   7,666  
Working Capital 40,485   30,619  
         

*Adjusted EBITDA is not a recognized measurement under International Financial Reporting Standards (“IFRS”) and this data may not be comparable to data presented by other companies. Management defines Adjusted EBITDA as EBITDA adjusted to exclude interest, tax, and depreciation, stock compensation, fair value changes and other non-cash items, and non-recurring items. This data is furnished to provide additional information and does not have any standardized meaning prescribed by IFRS. The Company uses this non-IFRS measure to provide shareholders and others with supplemental measures of its operating performance. The Company also believes that securities analysts, investors and other interested parties, frequently use this non-IFRS measure in the evaluation of companies, many of which present similar metrics when reporting their results….

(Excerpt) To read the full article , click here
Image credit: source